Anthony R. Means, PhD - Duke Medicine

Leadership Chancellor Administration Victor J. Dzau, MD R. Sanders Williams, MD Nancy Andrews, MD, PhD Catherine Lynch Gilliss, DNSc Asif Ahmad Monte D. Brown, MD Robert M. Califf, MD Michael Cuffe, MD Karen Frush, MD Mary Ann Fuchs, RN William J. Fulkerson Jr., MD Ranga R. Krishnan, MB ChB Kenneth C. Morris Michael J. Morsberger Paul Newman Molly O'Neill Robert L. Taber, PhD Douglas B. Vinsel Kerry Watson Huntington F. Willard, PhD Mark Newman, MD Kenneth Kreuzer, PhD Elizabeth DeLong, PhD Brigid Hogan, PhD J. Lloyd Michener, MD Thomas F. Tedder, PhD Harvey Jay Cohen, MD Thomas Petes, PhD James McNamara, MD Haywood Brown, MD David L. Epstein, MD Salvatore Pizzo, MD, PhD Joseph St. Geme III, MD Anthony R. Means, PhD Ranga R. Krishnan, MB ChB Christopher Willett, MD Carl E. Ravin, MD Danny O. Jacobs, MD Board Members
	Home > Leadership > Administration > Anthony R. Means, PhD Anthony R. Means, PhD Anthony Means, PhD, is a professor and chair of the Department of Pharmacology and Cancer Biology at Duke University Medical Center. A highly respected scientist, he has received numerous awards and is the author of more than 350 scholarly publications. Means earned both his undergraduate and master’s degrees from Oklahoma State University in Stillwater and his doctorate in endocrinology from the University of Texas in Austin. After spending a year in Australia for post-doctoral work in biochemistry at the University of Melbourne, Means worked as a visiting scientist in the endocrinology branch of the National Institutes of Health. He joined the faculty at Vanderbilt University School of Medicine in Nashville in 1969 as an assistant professor and associate director of the Vanderbilt Population Center. He held those positions until 1972, when he left Tennessee to become an associate professor in the department of cell biology and associate director of the Baylor Center for Population Research and Reproductive Biology at Baylor College of Medicine in Houston. He was promoted to full professor and vice chairman of the Department of Cell Biology at Baylor three years later, positions he held until coming to Duke to head the Department of Pharmacology in 1991. Means research at Duke focuses on the study of cell signals that regulate cell proliferation, differentiation or function, and how altering these pathways contributes to the onset of cancer. He hopes that improving the understanding of these pathways will provide clues that may be used to develop new drugs to combat the disease. Means has received national and international recognition for his work. He was awarded the Fred Conrad Koch Award by the Endocrine Society in 1998, and was elected fellow of the American Academy of Arts and Sciences, and the European Academy of Science in 2002. The following year, he was elected fellow of the American Association for the Advancement of Science and president-elect for the Endocrine Society.